非酒精性脂肪肝病与纤维化与痴呆发病及认知的关联:鹿特丹研究
在鹿特丹研究中,评估非酒精性脂肪肝病(NAFLD)和纤维化与痴呆发病及认知功能的关联。NAFLD和纤维化均与痴呆风险升高无关,NAFLD在FLI评估后5年内与痴呆风险显著降低相关(HR 0.48),且NAFLD与认知功能下降无关。
要点
- NAFLD和纤维化与痴呆风险升高无关。
- NAFLD在FLI评估后5年内与痴呆风险显著降低相关(HR 0.48)。
- NAFLD与多个认知域功能下降无关。
核心结论
- NAFLD和纤维化与痴呆发病风险升高无关,NAFLD也与认知功能受损无关。
- NAFLD在随访前5年内甚至具有保护作用,提示痴呆发病前NAFLD可能消退。
研究设计与样本
- 在鹿特丹研究(正在进行的前瞻性队列)中进行的纵向和横断面分析。
- 集1纳入1997-2002年访视且有脂肪肝指数(FLI)的3975名参与者,年龄70岁,随访15.5年。
- 集2纳入2009-2014年访视且有腹部超声的4577名参与者,年龄69.9岁,随访5.7年。
- 集3纳入2009-2014年访视且有肝硬度的3300名参与者,年龄67.6岁,随访5.6年。
- 排除标准为脂肪变性继发原因、现患痴呆和酒精数据缺失。
主要发现
- NAFLD和纤维化与痴呆风险升高无关:超声诊断NAFLD的HR 0.84(95%CI 0.61-1.16),FLI诊断NAFLD的HR 0.92(95%CI 0.69-1.22),纤维化的HR 1.07(95%CI 0.58-1.99),均为完全校正模型。
- NAFLD在FLI评估后5年内与痴呆发病风险显著降低相关(HR 0.48;95%CI 0.24-0.94)。
- NAFLD与多个认知域功能下降无关。
关键数值与推荐
- NAFLD定义为FLI≥60或超声显示脂肪变性。
- 纤维化定义为肝硬度≥8.0 kPa。
- 痴呆根据DSM-III-R定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) might affect brain health via the so-called liver-brain axis. Whether this results in an increased risk for dementia remains unclear. Therefore, we investigated the association of NAFLD and fibrosis with incident dementia and cognition among the elderly. METHODS: We performed longitudinal and cross-sectional analyses within the Rotterdam Study, an ongoing prospective cohort. Participants visiting between 1997 and 2002 with available fatty liver index (FLI) (set 1) or participants visiting between 2009 and 2014 with abdominal ultrasound (set 2) and liver stiffness (set 3) were included. Exclusion criteria were secondary causes for steatosis, prevalent dementia, and missing alcohol data. NAFLD was defined as FLI ≥60 or steatosis on ultrasound and fibrosis as liver stiffness ≥8.0 kPa. Dementia was defined according to the DSM-III-R. Associations between NAFLD, fibrosis, or liver stiffness and incident dementia were quantified using Cox regression. Finally, the association between NAFLD and cognitive function was assessed cross-sectionally. RESULTS: Set 1 included 3,975 participants (age 70 years, follow-up 15.5 years), set 2 4,577 participants (age 69.9 years, follow-up 5.7 years), and set 3 3,300 participants (age 67.6 years, follow-up 5.6 years). NAFLD and fibrosis were consistently not associated with an increased risk for dementia (NAFLD based on ultrasound, hazard rate [HR] 0.84, 95% CI 0.61-1.16; NAFLD based on FLI, HR 0.92, 95% CI 0.69-1.22; fibrosis, HR 1.07, 95% CI 0.58-1.99) in fully adjusted models. Of interest, NAFLD was associated with a significantly decreased risk for incident dementia until 5 years after FLI assessment (HR 0.48; 95% CI 0.24-0.94). Moreover, NAFLD was not associated with worse cognitive function, covering several domains. CONCLUSIONS: NAFLD and fibrosis were not associated with an increased risk for incident dementia, nor was NAFLD associated with impaired cognitive function. In contrast, NAFLD was even protective in the first 5 years of follow-up, hinting toward NAFLD regression before dementia onset. TRIAL REGISTRATION INFORMATION: Clinical Trial Number: NTR6831.
引用
- Xiao T, van Kleef LA, Ikram MK, et al. Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study. Neurology. 2022. PMID: 35618435. doi:10.1212/WNL.0000000000200770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。